|
|
|
|
| Advertisement |
 |
|
|
| Top Story |
 |
|
China's CAR-T Therapy Race |
With Nanjing Legend Biotech's cell self-reinfusion preparation receiving clinical trial approval from China's FDA last month, Jin Zhang looks at how the country's CAR-T therapy race is heating up
... /Read more/ |
|
|
| Europe |
 |
|
Plus ça change… |
Looking back at the agenda of a 1985 EFPIA conference, Reflector sees that, three decades on, the European drug industry is still seeking a pill for its own ills
... /Read more/ |
|
|
| Technology |
 |
|
A Watchful Eye on AI |
Julian Upton looks at the balance of optimism and caution discussed at eyeforpharma Barcelona around pharma's embrace of AI
... /Read more/ |
|
|
|
|
|
| Industry update |
| //Neurocentrx (Edinburgh, UK) appointed Nigel Brooksby as Non-Executive Chairman and Dr. Tim Corn as Non-Executive Director to take the company to a global market. // Argenx (Breda, The Netherlands and Ghent, Belgium) appointed R. Keith Woods as Chief Operating Officer. // Crescendo Biologics (Cambridge, UK) announced that Dani Bach has been appointed as Non-Executive Director of the company. // Affimed (Heidelberg, Germany) appointed Dr. Leila Alland as Chief Medical Officer. //
|
|
|
|
